Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluering av leveringen og effekten av THC-dampende væsker i blodstrømmen

10. november 2026 oppdatert av: Roswell Park Cancer Institute

Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Randomized Within-Subject Crossover Study

This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.

Studieoversikt

Detaljert beskrivelse

PRIMARY OBJECTIVES:

I. Assess pharmacokinetic (PK)/pharmacodynamic (PD) profiles of THC vaping liquids administered with co-use of vaped nicotine.

II. Outcomes of interest will be assessed overall, and according to biological sex.

SECONDARY OBJECTIVES:

I. Safety. II. Assessment of differences in puffing behaviors. III. Short-term subjective drug effects, and cognitive performance following THC use without nicotine versus (vs.) THC use with pre-nicotine use vs. THC use with post-nicotine use in current consumers of both vaped cannabis and vaped nicotine products.

OUTLINE: Participants are randomized to 1 of 3 arms.

ARM A: Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.

ARM B: Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.

ARM C: Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

After completion of study intervention, participants are followed up at 30 days.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Tidlig fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New York
      • Buffalo, New York, Forente stater, 14263
        • Roswell Park Cancer Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Danielle M. Smith

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 21 years of age; (self-reported on screening, verified at study visit).
  • Report use of commercial THC vaping cartridges for at least 3 months prior to enrollment; (self-reported).
  • Experience with THC potency at or above the study product AND experience with chasing THC with nicotine (at least monthly); (self-reported).
  • Report use of THC vaping liquids at least weekly (4x/month); (self-reported).
  • Daily use of nicotine vaping products containing >2% nicotine (>20mg/ml for at least 3 months prior to enrollment; (self-reported).
  • Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products/procedures.
  • Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#: NCE-STHC-1), semi-quantitative urinary THCA rapid test (NarcoCheck® THC Pre Dosage), and an illicit drug urine test (NarcoCheck® Évolutive®) during baseline testing, prior to receiving any study-related products.
  • Willing to abstain from nicotine use for 8 hours prior to each study session and abstain from cannabis use 1 day prior to each session.
  • Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion Criteria:

  • Unwilling or unable to follow protocol abstinence requirements based on more than two instances of a positive THC saliva test (NarcoCheck Ref#:NCE-S THC-1).

  • Illegal or non-prescription drug use within the past 90 days. As detected by NarcoCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product. THC use detected by NarcoCheck® Évolutive® is permitted

  • Illegal or non-prescription drug use/alcohol substance use disorder (SUD) within the past year; (self-reported).

  • Report drinking alcohol more than 3x per week with 5 or more drinks per occasions (males) or with 4 or more drinks per occasion; (women).

  • Report of daily cigarette use; (self-reported).

  • Current or prior diagnosis of schizophrenia, bipolar disorder, or other severe psychotic mental illness; (self-reported).

  • Current or prior diagnosis of myocardial infarction, arrhythmia, or congestive heart failure (self-reported)

  • Current or prior diagnosis of chronic obstructive pulmonary disorder (COPD), cystic fibrosis, pulmonary hypertension, pulmonary edema, pulmonary embolus, or other uncontrolled respiratory conditions

  • Current cancer diagnosis.

  • Pregnant, currently trying to become pregnant, or breastfeeding (females); (self-reported; pregnancy validated on study visit by urine test).

  • Regular use of medications that contain nicotine, induce CYP2A6, stimulants, or sympatholytics (e.g., beta-blockers); (self-reported).

  • Unwilling or unable to follow protocol requirements.

  • Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation.

  • The following special populations will be excluded:

    • Cognitively impaired adults/adults with impaired decision-making capacity
    • Individuals who are not yet adults (infants, children, teenagers)
    • Pregnant women
    • Prisoners
  • No children or person under the age of 21 will be involved in the study. While those under 21 may use cannabis smoked or vaping products, the legal age of purchasing and using those products in New York State is 21. The current legal age to purchase and use tobacco products in New York State (NYS) is 21. Thus, our provision of study product to adults aged 21 and older is in line with current NYS law.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A (placebo, THC, nicotine)

Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

Ancillary studies

Undergo blood collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Vape THC

Andre navn:
  • Cannabis sativa
  • Cannabis sativa blomstrende topp
  • Cannabis sativa Subsp. Blomstrende toppekstrakt
  • Cannabis sativa topp

Vape active nicotine

Andre navn:
  • (-)-Nikotin
  • NIC

Vape placebo nicotine

Eksperimentell: Arm B (placebo, THC, nicotine)

Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

Ancillary studies

Undergo blood collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Vape THC

Andre navn:
  • Cannabis sativa
  • Cannabis sativa blomstrende topp
  • Cannabis sativa Subsp. Blomstrende toppekstrakt
  • Cannabis sativa topp

Vape active nicotine

Andre navn:
  • (-)-Nikotin
  • NIC

Vape placebo nicotine

Eksperimentell: Arm C (placebo, THC, nicotine)

Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

Ancillary studies

Undergo blood collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Vape THC

Andre navn:
  • Cannabis sativa
  • Cannabis sativa blomstrende topp
  • Cannabis sativa Subsp. Blomstrende toppekstrakt
  • Cannabis sativa topp

Vape active nicotine

Andre navn:
  • (-)-Nikotin
  • NIC

Vape placebo nicotine

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Maximum concentration of THC in plasma (Cmax)
Tidsramme: Up to 21 days

Pharmacokinetics (PK) profiles of THC in plasma will be determined using a visual plot of plasma THC concentrations by time. Parameters will be derived using non-compartmental analysis in Phoenix WinNonlin and adjusted for baseline THC levels. Will be summarized by nicotine status using the appropriate descriptive statistics and graphical summaries.

Up to 21 days
Time to maximum concentration of THC in plasma (Tmax)
Tidsramme: Up to 21 days

Blood samples will be collected for plasma levels of THC. Parameters will be derived using linear mixed models.

Up to 21 days
Area under the plasma concentration-time curve from 0-120 minutes (AUC0-120)
Tidsramme: Up to 21 days

Blood samples will be collected for plasma levels of THC. Parameters will be derived using linear mixed models

Up to 21 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of adverse events (AEs)
Tidsramme: Up to 30 days after completion of study intervention

AEs will be summarized by nicotine condition and grade using frequencies and relative frequencies. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting.

Up to 30 days after completion of study intervention
Puffing behaviors
Tidsramme: Up to 21 days

puff duration

Up to 21 days
Puffing behaviors
Tidsramme: Up to 21 days

puff number

Up to 21 days
Short-term drug effects
Tidsramme: Up to 21 days

The short-term drug effects (Drug Effects Questionnaire [DEQ), The DEQ rates sixteen component items using a visual analog scale (0-100) to examine drug effects pre- and post-use

Up to 21 days
Marijuana Withdrawal Checklist [MWC)
Tidsramme: Up to 21 days

The Marijuana Withdrawal Questionnaire Total Score includes items assessing anxiety, depression, irritability, appetite, aggression/anger, sleep disturbance, somatic disturbances, and craving to use marijuana. The potential range of this total score is from "0" = no withdrawal symptoms to "47" = maximally high levels of withdrawal

Up to 21 days
Digit Symbol Substitution Task (DSST)
Tidsramme: Up to 21 days

An assessment of cognitive dysfunction that test ability to complete daily tasks

Up to 21 days
Paced Auditory Serial Addition Task (PASET)
Tidsramme: Up to 21 days

Measures of working memory and concentration .

Up to 21 days
Tobacco Craving Questionnaire (Short Form)
Tidsramme: Up to 21 days

Self reported 47-item questionnaire that assesses tobacco craving. Items are rated on a Likert-type scale from 1 (strongly disagree) to 7 (strongly agree). Factor scores for each participant are obtained by summing the three items in each factor scale, yielding a score ranging from 3 to 21.

Up to 21 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Danielle M Smith, Roswell Park Cancer Institute

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

15. desember 2026

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

7. mars 2024

Først innsendt som oppfylte QC-kriteriene

20. mars 2024

Først lagt ut (Faktiske)

27. mars 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • I-3597023
  • R01DA057228 (U.S. NIH-stipend/kontrakt)
  • I-3597023 (Annen identifikator: Roswell Park Cancer Institute)
  • NCI-2024-01556 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere